Table 1.
Case demographics, regions, antibodies, and probes used in the study
| Case | Age | Sex | PMI, hours | Clinical phenotypes | Pathological diagnosis | Braak LBD stage[8] | Regions and probes used for RNAscope | Region and antibodies used for IHC | Region used for single-nucleus RNA sequencing |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | F | n.a | PD | LBD | 4 | SN (SNCA, RBFOX3), amygdala (SNCA, RBFOX3, ALDH1L1) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 2 | 62 | F | 15 | PDD | LBD | 5 | SN (SNCA, RBFOX3), amygdala (SNCA, RBFOX3, ALDH1L1) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 3 | 81 | M | < 24 | PDD | LBD | 5 | SN (SNCA, RBFOX3), amygdala (SNCA, RBFOX3, ALDH1L1) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 4 | 62 | M | 4 | PD | LBD | 4 | SN (SNCA, RBFOX3) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 5 | 85 | M | n.a | PD | LBD | 4 | SN (SNCA, RBFOX3) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 6 | 52 | F | 38 | – | Control | None | SN (SNCA, RBFOX3), amygdala (SNCA, RBFOX3, ALDH1L1), pons (SNCA, Olig2) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 7 | 64 | F | n.a | – | Control | None | SN (SNCA, RBFOX3), amygdala (SNCA, RBFOX3, ALDH1L1), pons (SNCA, Olig2) | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 8 | 66 | M | 12 | – | Control | None | – | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 9 | 66 | M | 20 | – | Control | None | – | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 10 | 75 | M | 30 | – | Control | None | – | SN, basal ganglia, amygdala (SYN-1, 5G4) | – |
| 11 | 74 | M | 12.5 | – | Control | None | – | – | Frontal cortex |
| 12 | 74 | M | 6.3 | – | Control | None | – | – | Frontal cortex |
| 13 | 77 | M | 4 | – | Control | None | – | – | Frontal cortex |
IHC immunohistochemistry; LBD Lewy body disease; LPC Lewy pathology consensus criteria; n.a. not available; PD Parkinson’s disease; PDD Parkinson’s disease dementia; PMI postmortem interval; SN substantia nigra